AssetBag™ LT
MDI AseptiBag™ LT single-use storage and transfer systems are designed for cold chain applications in biopharmaceuticals. These systems are suitable for low-temperature storage of up to -80°C, as well as multiple freeze-thaw applications involving high-value drug substances and process intermediates.
MDI AseptiBag™ LT systems are made from low-extractable ULDPE film and provide robustness to ensure integrity at sub-zero temperatures during freezing, storage, transportation, and thawing.
MDI AseptiBag™ LT systems are used for long-term low-temperature storage of:
-
Process intermediates
-
Drug substances
-
Vaccine active raw materials (ARM)
-
Monoclonal Antibodies (mAbs)
-
Recombinant proteins
-
Compatible with long-term storage at temperatures up to -80°C
-
Withstands multiple freeze-thaw cycles
-
Very low extractable profile
-
High strength and flexibility
-
High transparency
| Film | Ultra-Low Density Polyethylene (ULDPE) |
| Operating Temperature | -80°C to 45°C |
| Storage Temperature | Up to -80°C |
| Sterilization | Gamma sterilizable up to 50 kGy |
| 100% Integrity Tested | Each system tested to comply with validated Acceptable Integrity Test Specifications |
| Pressure Endurance | Validated to endure operating and burst pressure with liquid for user and product safety |
| Temperature Endurance | AseptiBag™ LT systems are validated to endure wide temperature conditions which may be encountered during use |
| Bioburden Testing | Bioburden is tested as per ISO 117 37-1 and assured to be <1000 cfu/bag |
| Biosafety | Passes Biological Reactivity test, In-Vivo, as per USP <88> for Class VI plastics. Passes the Biological Reactivity Tests, In Vitro for Cytotoxicity as described in USP <87>. |
| Extractables | Extractables/leachables from bags, used at various stages of a biopharmaceutical manufacturing process, will add on and may impact the impurity profile of the desired product |
| Particulate Matter | AseptiBag™ LT systems are validated for particulate matter in injections as per USP <788> and visible particulates in injections as per USP <790> |
| Sterility Assurance | mdi AseptiBag™ LT systems are sterilized by gamma irradiation to provide a sterility assurance level of 10-6. The sterilization process has been validated as per ISO 11137-2 which includes dose verification, dose mapping and quarterly dose audit
The sterilization dose of 25 kGy has been substantiated through careful definition of the test samples, bio-burden testing of multiple lots of the selected test samples, calculation of verification dose and sterility testing. |
| Bacterial Endotoxin | Aqueous extracts exhibit < 0.25 EU/ml as established by Limulus Amebocyte Lysate (LAL) Test as per USP <85> |
| File Type | Download |
|---|---|
| Datasheet | Download |
Have questions or need assistance?
Our team is here to help! Contact us today, and we’ll get back to you as soon as possible.